BERLIN, April 7 (Reuters) - Germany's vaccine advisory
committee sees no disadvantages or risks from giving younger
recipients of AstraZeneca's COVID-19 vaccine a second
dose of an alternative shot, two of its members said on
Wednesday.
"Nobody expects from an immunological perspective that there
will be a disadvantage to getting a second dose of another
vaccine," Marianne Roebl-Mathieu, a member of the standing
committee on vaccinations, told an online briefing.
Studies involving mixing vaccine doses are underway.
The German committee recommended last week that people aged
under 60 who had received one shot of the AstraZeneca vaccine
should get a second dose of another vaccine following reports of
rare blood clotting events.
Should a second dose prove ineffective, a third dose could
be effective, added Roeble Mathieu. Her colleague on the panel,
Christian Bogdan, said he had seen no evidence linking other
vaccines to the rare blood clotting disorders.
(Reporting by Douglas Busvine, Editing by John Miller)